✦ LIBER ✦

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

✍ Scribed by Ayman Al-Shurbaji; Juliette Säwe

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Relationship between fluvoxamine pharmac

✍ O. Spigset; K. Granberg; S. Hägg; Å. Norström; R. Dahlqvist 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 155 KB

Polymorphism of CYP2D6, CYP2C19, CYP2C9

✍ Jónrit Halling; Maria S. Petersen; Per Damkier; Flemming Nielsen; Philippe Grand 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 290 KB

Genotypes for the cytochrome P450 enzyme

✍ L. Bathum; K. Andersen-Ranberg; J. Boldsen; K. Brøsen; B. Jeune 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 138 KB

Dose-dependent inhibition of CYP1A2, CYP

✍ U. Jeppesen; L. F. Gram; K. Vistisen; S. Loft; H. E. Poulsen; K. Brøsen 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 95 KB

Pharmacokinetics and pharmacodynamics of

✍ T. Fukasawa; N. Yasui–Furukori; A. Suzuki; Y. Inoue; T. Tateishi; K. Otani 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 103 KB

The CYP2C8 inhibitor gemfibrozil does no

✍ Tiina Karonen; Pertti J. Neuvonen; Janne T. Backman 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 141 KB